A Real-world Retrospective Study of Disease Outcomes in Non-severe COVID-19 Patient

Inclusion Criteria: 1. Age ≥18 years old; 2. A record of positive SARS-CoV-2 nucleic acid test results on the day of admission or on the second day; 3. Diagnosed as mild or common novel coronavirus pneumonia on admission, or with at least one of the following COVID-19-related symptoms on admission: fever, cough, sore throat, nasal congestion or runny nose, headache, muscle pain, nausea, vomiting, diarrhea , shortness of breath or difficulty breathing, chills or chills; 4. Documented or diagnosed high risk factors for progression to severe COVID-19 (including death) with one or more of the following: * Age ≥ 60 years * Cardiovascular disease (including congenital heart disease) or high blood pressure * Chronic lung disease (eg chronic obstructive pulmonary disease \[COPD\], asthma \[moderate to severe\], interstitial lung disease, cystic fibrosis and pulmonary hypertension) * diabetes * Has an immunosuppressive disorder or is receiving immunosuppressive therapy (eg, long-term use of corticosteroids or other immunosuppressive drugs leading to decreased immune function) * Obese or overweight (BMI\>25 kg/m2) * Sickle cell disease * Active cancer * Chronic kidney disease * Current smokers * Neurodevelopmental disorders (eg, cerebral palsy, Down syndrome) or other conditions that cause medical complexity (eg, genetic or metabolic syndrome and severe congenital anomalies) * Need for relevant medical support (not related to COVID-19) (eg tracheostomy, gastrostomy or positive pressure ventilation, etc.) Exclusion Criteria: 1. Diagnosed with severe/critical COVID-19 before or on the day of admission; 2. There is a data record of having received the following treatments before progression to severe/critical COVID-19: * Nematicavir/ritonavir combination package (ie Paxlovid) * SARS-CoV-2 monoclonal antibody (Ambavirumab/Romisevirumab) * Convalescent COVID-19 plasma * Other anti-SARS-CoV-2 drugs under investigation